Cited by 1,649Epigenetics and DNA MethylationCancer Cells and MetastasisMechanisms of cancer metastasis

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Open access

Kleer, Celina G., Cao, Qi, Varambally, Sooryanarayana, Shen, Ronglai, Ota, Ichiro, Tomlins, Scott A., Ghosh, Debashis, Sewalt, Richard G. A. B., Otte, Arie P., Hayes, Daniel F., Sabel, Michael S., Livant, Donna, Weiss, Stephen J., Rubin, Mark A., Chinnaiyan, Arul M.·2003·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1933744100PMC PMC208805

Open this paper in CoChat — free account

Abstract

The Polycomb Group Protein EZH2 is a transcriptional repressor involved in controlling cellular memory and has been linked to aggressive prostate cancer. Here we investigate the functional role of EZH2 in cancer cell invasion and breast cancer progression. EZH2 transcript and protein were consistently elevated in invasive breast carcinoma compared with normal breast epithelia. Tissue microarray analysis, which included 917 samples from 280 patients, demonstrated that EZH2 protein levels were strongly associated with breast cancer aggressiveness. Overexpression of EZH2 in immortalized human mammary epithelial cell lines promotes anchorage-independent growth and cell invasion. EZH2-mediated cell invasion required an intact SET domain and histone deacetylase activity. This study provides compelling evidence for a functional link between dysregulated cellular memory, transcriptional repression, and neoplastic transformation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.1933744100

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Ki67 expression in breast cancer
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Cancer Statistics, 2003
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Self-citation
Diseases of the Breast
Haagenson, C. (1971) · Cited by 1,773

Flagged first, then by citations

Show all 38 references

1 of the 38 references couldn’t be matched to a known paper.

Research works printed but not linked: 7

Ellis M. Hayes D. & Lippman M. (2000) in Diseases of the Breast eds. Harris J. Lippman M. E. & Morrow M. (Lippincott–Raven Philadelpha) pp. 749–798.
Clark G. M. (1996) in Diseases of the Breast eds. Harris. J. L. M.. Morrow M. & Hellman S. (Lippincott–Raven Philadephia) pp. 461–485.
Tie, F., Furuyama, T., Prasad-Sinha, J., Jane, E. & Harte, P. J. (2001) Development (Cambridge, U.K.) 128, 275–286.
Livant, D. L., Linn, S., Markwart, S. & Shuster, J. (1995) Cancer Res. 55, 5085–5093.7585556
Rhodes, D. R., Barrette, T. R., Rubin, M. A., Ghosh, D. & Chinnaiyan, A. M. (2002) Cancer Res. 62, 4427–4433.12154050
Gruvberger, S., Ringner, M., Chen, Y., Panavally, S., Saal, L. H., Borg, A., Ferno, M., Peterson, C. & Meltzer, P. S. (2001) Cancer Res. 61, 5979–5984.11507038
Livant, D. L., Brabec, R. K., Pienta, K. J., Allen, D. L., Kurachi, K., Markwart, S. & Upadhyaya, A. (2000) Cancer Res. 60, 309–320.10667582

Sorted by citations

Items 401–500 of 1,000

Polycomb group protein EZH2‐mediated E‐cadherin repression promotes metastasis of oral tongue squamous cell carcinoma
Wang, C., Liu, X., Chen, Z., Huang, H., Jin, Y., Kolokythas, A., Wang, A., Dai, Y. D., Wong, D. T., & Zhou, X. C. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.21848 · Cited by 94
The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells
Yu, T., Wang, Y., Hu, Q., Wu, W., Wu, Y., Wei, W., Han, D., You, Y., Lin, N., & Liu, N. (2017) · Oncotarget · doi:10.18632/oncotarget.21311 · Cited by 99
Cancer-linked targets modulated by curcumin.
Hasima, N., & Aggarwal, B. B. (2012) · PubMed Central · Cited by 92
Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance
Kikuchi, J., Kinoshita, I., Shimizu, Y., Kikuchi, E., Konishi, J. S., Oizumi, S., Kaga, K., Matsuno, Y., Nishimura, M., & Dosaka‐Akita, H. (2010) · Cancer · doi:10.1002/cncr.25128 · Cited by 94
Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition
Malouf, G. G., Taube, J. H., Lu, Y., Roysarkar, T., Panjarian, S. B., Estecio, M. R., Jelı́nek, J., Yamazaki, J., Raynal, N. J. ‐., Long, H., et al. (2013) · Genome biology · doi:10.1186/gb-2013-14-12-r144 · Cited by 98
Inner workings and regulatory inputs that control Polycomb repressive complex 2
O’Meara, M., & Simon, J. A. (2012) · Chromosoma · doi:10.1007/s00412-012-0361-1 · Cited by 99
Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis
Zeng, Y., Qiu, R., Yang, Y., Gao, T., Zheng, Y., Huang, W., Gao, J., Zhang, K., Liu, R., Wang, S., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.004 · Cited by 92
Epithelial and Stromal Cathepsin K and CXCL14 Expression in Breast Tumor Progression
Kleer, C. G., Bloushtain-Qimron, N., Chen, Y., Carrasco, D. R., Hu, M. S., Yao, J., Kraeft, S., Collins, L. C., Sabel, M. S., Argani, P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0732 · Cited by 92
Self-citation
The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states
Wigle, T. J., Knutson, S. K., Jin, L., Kuntz, K. W., Pollock, R. M., Richon, V. M., Copeland, R. A., & Scott, M. P. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.08.018 · Cited by 94
Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage
Wu, Z., Lee, S. T., Qiao, Y., Li, Z., Lee, P. L., Lee, Y. J., Jiang, X., Tan, J. Y., Aau, M., Lim, C. Z. H., et al. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.48 · Cited by 95
Propagation of Silencing
Lavigne, M., Francis, N. J., King, I. F. G., & Kingston, R. E. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00006-1 · Cited by 95
The inhibition of EZH2 ameliorates osteoarthritis development through the Wnt/β-catenin pathway
Chen, L., Wu, Y., Wu, Y. R., Wang, Y., Sun, L., & Li, F. (2016) · Scientific Reports · doi:10.1038/srep29176 · Cited by 95
Role of Transcriptional Corepressor CtBP1 in Prostate Cancer Progression
Wang, R., Asangani, I. A., Chakravarthi, B. V. S. K., Ateeq, B., Lonigro, R. J., Cao, Q., Mani, R. S., Camacho, D. F., McGregor, N., Schumann, T., et al. (2012) · Neoplasia · doi:10.1593/neo.121192 · Cited by 93
Self-citation
MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells
Dang, X., Ma, A., Yang, L., Hao, H., Zhu, B., Shang, D., Chen, T., & Luo, Y. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.01.002 · Cited by 91
Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia
Grubach, L., Juhl‐Christensen, C., Rethmeier, A., Olesen, L. H., Aggerholm, A., Hokland, P., & Østergaard, M. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01083.x · Cited by 93
Targetable activating mutations are very frequent in GCB and ABC diffuse large B‐cell lymphoma
Bohers, É., Mareschal, S., Bouzelfen, A., Marchand, V., Ruminy, P., Maingonnat, C., Ménard, A., Etancelin, P., Bertrand, P., Dubois, S., et al. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22126 · Cited by 93
Comparative methylome analysis in solid tumors reveals aberrant methylation at chromosome 6p in nasopharyngeal carcinoma
Dai, W., Cheung, A. K. L., Ko, J. M. Y., Cheng, Y., Zheng, H., Ngan, R. K., Ng, W. T., Lee, A. W. M., Yau, C. C., Lee, V. H.-F., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.451 · Cited by 92
NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2
Hu, P., Chu, J., Wu, Y., Sun, L., Lv, X., Zhu, Y., Li, J., Guo, Q., Gong, C., Liu, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5609 · Cited by 90
The role of nuclear organization in cancer
Lever, E., & Sheer, D. (2009) · The Journal of Pathology · doi:10.1002/path.2651 · Cited by 93
EZH2, Ki‐67 and MCM7 are prognostic markers in prostatectomy treated patients
Laitinen, S., MARTIKAINEN, P. M., Tolonen, T. T., Isola, J. J., Tammela, T. L. J., & Visakorpi, T. (2007) · International Journal of Cancer · doi:10.1002/ijc.23145 · Cited by 90
Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions
Guellec, S. L., Macagno, N., Velasco, V., Lamant, L., Lae, M. E., Filleron, T., Malissen, N., Cassagnau, E., Terrier, P., Chevreau, C., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.91 · Cited by 90
PRDM5 Identified as a Target of Epigenetic Silencing in Colorectal and Gastric Cancer
Watanabe, Y., Toyota, M., Kondo, Y., Suzuki, H., Imai, T., Ohe-Toyota, M., Maruyama, R., Nojima, M., Sasaki, Y., Sekido, Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0305 · Cited by 89
Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31
Zhang, Q., Padi, S. K. R., Tindall, D. J., & Guo, B. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.454 · Cited by 92
EZH2 as a potential target in cancer therapy
McCabe, M. T., & Creasy, C. L. (2014) · Epigenomics · doi:10.2217/epi.14.23 · Cited by 91
KDM4B is a Master Regulator of the Estrogen Receptor Signalling Cascade
Gaughan, L., Stockley, J., Coffey, K., O'Neill, D. J., Jones, D., Wade, M., Wright, J., Moore, M., Tse, S., Rogerson, L., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt469 · Cited by 78
Epigenetics of Cancer Progression
Vucic, E. A., Brown, C. J., & Lam, W. L. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.2.215 · Cited by 89
Deregulated expression of Polycomb-group oncogenes in human malignant lymphomas and epithelial tumors
Raaphorst, F. M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi111 · Cited by 89
EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic cancer
Han, T., Jiao, F., Hu, H. X., Yuan, C., Wang, L., Jin, Z., Song, W., & Wang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7156 · Cited by 88
EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells
Zhao, Y., Wang, X., Wu, W., Long, H., Huang, J., Wang, Z., Li, T., Tang, S., Zhu, B., & Chen, D. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.07.039 · Cited by 91
Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer
Karamitopoulou, E., Pallante, P., Zlobec, I., Tornillo, L., Carafa, V., Schaffner, T. J., Borner, M., Diamantis, I. D., Esposito, F., Brunner, T., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.01.033 · Cited by 89
FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells
Du, J., Li, L., Ou, Z., Kong, C., Zhang, Y., Dong, Z., Zhu, S., Jiang, H., Shao, Z., Huang, B., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1396-3 · Cited by 90
HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer
Mahara, S., Lee, P. L., Feng, M., Tergaonkar, V., Chng, W. J., & Yu, Q. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602079113 · Cited by 87
Chromatin, cancer and drug therapies
Cortez, C. C., & Jones, P. A. (2008) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2008.07.006 · Cited by 92
Expression of polycomb group protein EZH2 in nevi and melanoma
McHugh, J. B., Fullen, D. R., Ma, L., Kleer, C. G., & Su, L. D. (2006) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2006.00678.x · Cited by 89
Self-citation
Transcriptional and epigenetic networks of helper T and innate lymphoid cells
Shih, H., Sciumè, G., Poholek, A. C., Vahedi, G., Hirahara, K., Villarino, A. V., Bonelli, M. M., Bosselut, R., Kanno, Y., Muljo, S. A., et al. (2014) · Immunological Reviews · doi:10.1111/imr.12208 · Cited by 91
Context-dependent actions of Polycomb repressors in cancer
Koppens, M. A. J., & van Lohuizen, M. (2015) · Oncogene · doi:10.1038/onc.2015.195 · Cited by 88
Genome‐wide methylation screen in low‐grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis
Faryna, M., Konermann, C., Aulmann, S., Bermejo, J. L., Brugger, M., Diederichs, S., Rom, J., Weichenhan, D., Claus, R., Rehli, M., et al. (2012) · The FASEB Journal · doi:10.1096/fj.12-209502 · Cited by 86
Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity
Goldman, S. L., Hassan, C., Khunte, M., Soldatenko, A., Jong, Y., Afshinnekoo, E., & Mason, C. E. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00133 · Cited by 90
Post-translational modifications of EZH2 in cancer
Li, Z., Li, M., Wang, D., Hou, P., Chen, X., Chu, S., Chai, D., Zheng, J., & Bai, J. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00505-0 · Cited by 87
Targeting the enhancer of zeste homologue 2 in medulloblastoma
Alimova, I. N., Venkataraman, S., Harris, P. S., Márquez, V. E., Northcott, P. A., Dubuc, A. M., Taylor, M. D., Foreman, N. K., & Vibhakar, R. (2012) · International Journal of Cancer · doi:10.1002/ijc.27455 · Cited by 87
Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells
Curry, E. W., Green, I., Chapman‐Rothe, N., Shamsaei, E., Kandil, S., Cherblanc, F., Payne, L., Bell, E., Ganesh, T., Srimongkolpithak, N., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0118-9 · Cited by 91
Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesisPreprint
Wassef, M. A., Rodilla, V., Teissandier, A., Zeitouni, B., Gruel, N., Sadacca, B., Irondelle, M., Charruel, M., Ducos, B., Michaud, A., et al. (2015) · Genes & Development · doi:10.1101/gad.269522.115 · Cited by 95
TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep)
Cheng, L. L., Itahana, Y., Lei, Z. D., Chia, N., Wu, Y., Yu, Y., Zhang, S. L., Thike, A. A., Pandey, A., Rozen, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0036 · Cited by 89
EZH2 inhibits NK cell–mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner
Bugide, S., Gupta, R., Green, M. R., & Wajapeyee, N. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102718118 · Cited by 86
A Putative Role for Psoriasin in Breast Tumor Progression
Krop, I. E., März, A., Carlsson, H., Li, X., Bloushtain-Qimron, N., Hu, M., Gelman, R. S., Sabel, M. S., Schnitt, S. J., Ramaswamy, S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1523 · Cited by 85
Self-citation
MicroRNA-31 Is a Transcriptional Target of Histone Deacetylase Inhibitors and a Regulator of Cellular Senescence
Cho, J.-H., Dimri, M., & Dimri, G. P. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.624361 · Cited by 87
Linking cell signaling and the epigenetic machinery
Mohammad, H. P., & Baylin, S. B. (2010) · Nature Biotechnology · doi:10.1038/nbt1010-1033 · Cited by 85
Polycomb genes and cancer: Time for clinical application?
Crea, F., Paolicchi, E., Márquez, V. E., & Danesi, R. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.10.007 · Cited by 87
miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation
Zhang, W., Chen, J., Shan, T., Aguilera‐Barrantes, I., Wang, L., Huang, T. H. ‐., Rader, J. S., Sheng, X., & Huang, Y. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0092-x · Cited by 84
The master regulator FUBP1: its emerging role in normal cell function and malignant development
Debaize, L., & Troadec, M. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2933-6 · Cited by 86
Corepressor Protein CDYL Functions as a Molecular Bridge between Polycomb Repressor Complex 2 and Repressive Chromatin Mark Trimethylated Histone Lysine 27
Zhang, Y., Yang, X., Gui, B., Xie, G., Zhang, D., Shang, Y., & Liang, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.271064 · Cited by 89
Down-Regulation of the Histone Methyltransferase EZH2 Contributes to the Epigenetic Programming of Decidualizing Human Endometrial Stromal Cells
Grimaldi, G., Christian, M., Steel, J. H., Henriet, P., POUTANEN, M. H., & Brosens, J. J. (2011) · Molecular Endocrinology · doi:10.1210/me.2011-1139 · Cited by 85
Histone modification enzymes: novel targets for cancer drugs
Kristeleit, R. S., Stimson, L., Workman, P., & Aherne, W. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.1.135 · Cited by 86
Statins inhibit tumor progression via an enhancer of zeste homolog 2‐mediated epigenetic alteration in colorectal cancer
Ishikawa, S., Hayashi, H., Kinoshita, K., Abe, M., Kuroki, H., Tokunaga, R., Tomiyasu, S., Tanaka, H., Sugita, H., Arita, T., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28672 · Cited by 85
Senescence-Associated Pro-inflammatory Cytokines and Tumor Cell Plasticity
Vernot, J. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00063 · Cited by 85
Epigenetic regulation of cancer stem cell formation and maintenance
French, R., & Pauklin, S. (2020) · International Journal of Cancer · doi:10.1002/ijc.33398 · Cited by 87
Multifaceted role of EZH2 in breast and prostate tumorigenesis
Deb, G., Thakur, V. S., & Gupta, S. (2013) · Epigenetics · doi:10.4161/epi.24532 · Cited by 92
The N Terminus of Drosophila ESC Binds Directly to Histone H3 and Is Required for E(Z)-Dependent Trimethylation of H3 Lysine 27
Tie, F., Stratton, C. A., Kurzhals, R. L., & Harte, P. J. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01822-06 · Cited by 90
Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer
Hoffmann, M. J., Engers, R., Florl, A. R., Otte, A. P., Müller, M., & Schulz, W. A. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.9.4542 · Cited by 85
Self-citation
Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program
Hirukawa, A., Smith, H. W., Zuo, D., Dufour, C. R., Savage, P., Bertos, N., Johnson, R. M., Bui, T., Bourque, G., Basik, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04864-8 · Cited by 85
Effects of rearrangement and allelic exclusion of JJAZ1 / SUZ12 on cell proliferation and survival
Li, H., Ma, X., Wang, J., Koontz, J. I., Nucci, M. R., & Sklar, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709986104 · Cited by 83
Deletion of Polycomb Repressive Complex 2 From Mouse Intestine Causes Loss of Stem Cells
Koppens, M. A. J., Bounova, G., Gargiulo, G., Tanger, E., Janssen, H., Cornelissen‐Steijger, P., Blom, M., Song, J., Wessels, L. F. A., & van Lohuizen, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.06.020 · Cited by 89
TRIM28 interacts with EZH2 and SWI/SNF to activate genes that promote mammosphere formation
Li, J.-D., Xi, Y., Li, W., McCarthy, R. L., Stratton, S. A., Zou, W., Li, W., Dent, S., Jain, A. K., & Barton, M. C. (2017) · Oncogene · doi:10.1038/onc.2016.453 · Cited by 81
Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl
Paccez, J. D., Duncan, K., Sekar, D., Correa, R. G., Wang, Y., Gu, X., Bashin, M., Chibale, K., Libermann, T. A., & Zerbini, L. F. (2019) · Oncogenesis · doi:10.1038/s41389-019-0122-6 · Cited by 81
Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer
Toy, K. A., Valiathan, R. R., Núñez, F. M., Kidwell, K., González, M. E., Fridman, R. A., & Kleer, C. G. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3285-7 · Cited by 81
Self-citation
The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer
Kodach, L. L., Jacobs, R. J., Heijmans, J., van Noesel, C. J. M., Langers, A. M. J., Verspaget, H. W., Hommes, D. W., Offerhaus, G. J. A., van den Brink, G. R., & Hardwick, J. C. H. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq147 · Cited by 83
Targeting histone methyltransferase EZH2 as cancer treatment
Kondo, Y. (2014) · The Journal of Biochemistry · doi:10.1093/jb/mvu054 · Cited by 82
O -GlcNAcylation regulates the stability and enzymatic activity of the histone methyltransferase EZH2
Lo, P.-W., Shie, J., Chen, C., Wu, C., Hsu, T.-L., & Wong, C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801850115 · Cited by 86
Downregulation of Enhancer of Zeste Homolog 2 (EZH2) is essential for the Induction of Autophagy and Apoptosis in Colorectal Cancer Cells
Yao, Y., Hu, H., Yang, Y., Zhou, G., Shang, Z., Yang, X., Sun, K., Zhan, S., Yu, Z., Li, P., et al. (2016) · Genes · doi:10.3390/genes7100083 · Cited by 80
Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer
Abdel-Hafiz, H. A. (2017) · Diseases · doi:10.3390/diseases5030016 · Cited by 84
RETRACTED ARTICLE: Lnc-PDZD7 contributes to stemness properties and chemosensitivity in hepatocellular carcinoma through EZH2-mediated ATOH8 transcriptional repression
Zhang, Y., Tang, B., Song, J. H., Yu, S., Yang, L., Su, H., & He, S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1106-2 · Cited by 81
Retracted
Regulation of CCL2 by EZH2 affects tumor-associated macrophages polarization and infiltration in breast cancer
Wang, Y., Lei, Y., Hu, Z.-L., Fang, Y.-F., Shen, Y., Song, M., & Chen, Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05169-x · Cited by 84
Feature Selection and Molecular Classification of Cancer Using Genetic Programming
Yu, J., Yu, J., Almal, A. A., Dhanasekaran, S. M., Ghosh, D., Worzel, W. P., & Chinnaiyan, A. M. (2007) · Neoplasia · doi:10.1593/neo.07121 · Cited by 79
Self-citation
Long non-coding RNAs in cancer invasion and metastasis
Shen, X.-H., Qi, P., & Du, X. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.75 · Cited by 79
EZH2 Promotes Malignant Behaviors via Cell Cycle Dysregulation and Its mRNA Level Associates with Prognosis of Patient with Non-Small Cell Lung Cancer
Cao, W., Ribeiro, R. D. O., Liu, D., Saintigny, P., Xia, R., Xue, Y., Lin, R., Mao, L., & Ren, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052984 · Cited by 80
MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer
Kato, M., Goto, Y., Matsushita, R., Kurozumi, A., FUKUMOTO, I., Nishikawa, R., Sakamoto, S., Enokida, H., Nakagawa, M., Ichikawa, T., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3043 · Cited by 80
miR-26a inhibits invasion and metastasis of nasopharyngeal cancer by targeting EZH2
Li, Y., Lü, J., Zhang, B., Liu, X., Wang, L., Li, S.-Y., Peng, X., Xu, X., Tian, W., & Li, X. (2013) · Oncology Letters · doi:10.3892/ol.2013.1173 · Cited by 79
Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors
Baker, T. E., Nerle, S., Pritchard, J. R., Zhao, B., Rivera, V. M., Garner, A. P., & Gonzalvez, F. (2015) · Oncotarget · doi:10.18632/oncotarget.5066 · Cited by 80
Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1
Chaib, H., Nebbioso, A., Prébet, T., Castellano, R., Garbit, S., Restouin, A., Vey, N., Altucci, L., & Collette, Y. (2011) · Leukemia · doi:10.1038/leu.2011.271 · Cited by 80
Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role
Clermont, P.-L., Sun, L., Crea, F., Thu, K. L., Zhang, A., Parolia, A., Lam, W. L., & Helgason, C. D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.474 · Cited by 80
The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing
Nuytten, M., Beke, L., Eynde, A. V., Ceulemans, H., Beullens, M., Hummelen, P. V., Fuks, F., & Bollen, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210774 · Cited by 86
SUZ12 Promotes Human Epithelial Ovarian Cancer by Suppressing Apoptosis via Silencing HRK
Li, H., Cai, Q. K., Wu, H. G., Vathipadiekal, V., Dobbin, Z. C., Li, T., Xiang, H., Landen, C. N., Birrer, M. J., Sánchez‐Beato, M., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0335 · Cited by 80
Chromatin-modifying enzymes as therapeutic targets – Part 1
Keppler, B. R., & Archer, T. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.10.1301 · Cited by 89
Transcriptional Regulation of Arabidopsis Polycomb Repressive Complex 2 Coordinates Cell-Type Proliferation and Differentiation
de Lucas, M., Pu, L., Turco, G. M., Gaudinier, A., Morao, A. K., Harashima, H., Kim, D., Ron, M., Sugimoto, K., Roudier, F., et al. (2016) · The Plant Cell · doi:10.1105/tpc.15.00744 · Cited by 84
EZH2 cooperates with gain‐of‐function p53 mutants to promote cancer growth and metastasis
Zhao, Y., Ding, L., Wang, D., Ye, Z., He, Y., Ma, L., Zhu, R., Pan, Y., Wu, Q., Pang, K., et al. (2019) · The EMBO Journal · doi:10.15252/embj.201899599 · Cited by 81
Common features of chromatin in aging and cancer: cause or coincidence?
Zane, L. K., Sharma, V., & Misteli, T. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.07.001 · Cited by 79
Clinical Presentation of Preeclampsia and the Diagnostic Value of Proteins and Their Methylation Products as Biomarkers in Pregnant Women with Preeclampsia and Their Newborns
Portelli, M., & Baron, B. (2018) · Journal of Pregnancy · doi:10.1155/2018/2632637 · Cited by 84
VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2–Targeted Therapy
Riquelme, E. M., Suraokar, M. B., Behrens, C., Lin, H. Y., Girard, L., Nilsson, M. B., Simon, G. R., Wang, J., Coombes, K. R., Lee, J. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1916 · Cited by 77
Current Status of Long Non-Coding RNAs in Human Breast Cancer
Cerk, S., Schwarzenbacher, D., Adiprasito, J. B., Stotz, M., Hutterer, G. C., Gerger, A., Ling, H. Y., Călin, G. A., & Pichler, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091485 · Cited by 76
DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment
Sarno, F., Nebbioso, A., & Altucci, L. (2019) · Epigenetics · doi:10.1080/15592294.2019.1699991 · Cited by 76
EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6
Patil, S., Steuber, B., Kopp, W., Kari, V., Urbach, L., Wang, X., Küffer, S., Bohnenberger, H., Spyropoulou, D., Zhang, Z., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0672 · Cited by 79
Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer
Yeh, C.-M., Shay, J., ZENG, T.-C., Chou, J.-L., Huang, T. H. ‐., Lai, H., & Chan, M. W. Y. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2627 · Cited by 76
JNK and STAT3 signaling pathways converge on Akt-mediated phosphorylation of EZH2 in bronchial epithelial cells induced by arsenic
Chen, B., Liu, J., Chang, Q., Beezhold, K., Lu, Y., & Chen, F. (2012) · Cell Cycle · doi:10.4161/cc.23030 · Cited by 76
Keynote review: Chromatin control and cancer-drug discovery: realizing the promise
Inche, A. G., & Thangue, N. B. L. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03691-3 · Cited by 77
Epigenetic regulation of endothelial‐cell‐mediated vascular repair
Fraineau, S., Palii, C. G., Allan, D., & Brand, M. (2014) · FEBS Journal · doi:10.1111/febs.13183 · Cited by 80
Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16INK4A, p27KIP1, p21WAF1, Ki‐67 expression patterns in gastric cancer
Mattioli, E., Vogiatzi, P., Sun, A., Abbadessa, G., Angeloni, G., D’Ugo, D., Trani, D., Gaughan, J., Vecchio, F. M., Cevenini, G., et al. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20833 · Cited by 76
Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.
Fan, T.-Y., Wang, H., Peng, X., Liu, Y., Li, H., Lei, B., Yu, M., & Qi, S. (2014) · PubMed Central · Cited by 76
Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside
Korfhage, J. L., & Lombard, D. B. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0147 · Cited by 78
Epigenetic cancer therapy: Proof of concept and remaining challenges
Mund, C., & Lyko, F. (2010) · BioEssays · doi:10.1002/bies.201000061 · Cited by 77
Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy
Gu, Y., Zhang, Z., & ten Dijke, P. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-00980-8 · Cited by 78

Authors: Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., Sabel, M. S., Livant, D., Weiss, S. J., Rubin, M. A., & Chinnaiyan, A. M.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Kleer, Celina G.
Cao, Qi
Varambally, Sooryanarayana
Shen, Ronglai
Ota, Ichiro
Tomlins, Scott A.
Hayes, Daniel F.
Sabel, Michael S.
Weiss, Stephen J.
Rubin, Mark A.
Chinnaiyan, Arul M.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2003-09-19
Volume: 100
Issue: 20
Pages: 11606-11611
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1933744100
PMC: PMC208805
OpenAlex: W2100365251
Cited by: 1,649
References: 38
Citations by year: 2026: 21 · 2025: 43 · 2024: 53 · 2023: 72 · 2022: 55 · 2021: 67 · 2020: 94 · 2019: 69 · 2018: 83 · 2017: 91 · 2016: 109 · 2015: 109 · 2014: 116 · 2013: 114 · 2012: 108
FWCI: 12.78
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
UvA-DARE (University of Amsterdam) (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: National Cancer Institute (P50-CA-69568, R01CA097063, R01 CA97063, P50CA069568)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Keywords: EZH2, Polycomb group proteins, breast cancer aggressiveness, breast cancer progression, cell invasion, anchorage-independent growth, oncogenic transformation, mammary epithelial cells, SET domain, histone deacetylase activity, transcriptional repression, cellular memory, prognostic factors
MeSH terms: Enhancer of Zeste Homolog 2 Protein, Breast, Breast Neoplasms, Cell Transformation, Neoplastic, DNA-Binding Proteins, Epithelial Cells, Female, Humans, Immunohistochemistry, Proteins, RNA, Messenger, Transcription Factors, Polymerase Chain Reaction, Polycomb Repressive Complex 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks